Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1–34) analogs in women

Compared with PTH analogs, ROMO offers stronger short-term protection against osteoporotic fractures and hypercalcemia, particularly in older women with prior fractures. Nonetheless, cardiovascular safety, calcium metabolism, and sequential therapy require careful consideration for individualized treatment.